Acetic Acid — predicted protein targets

Known targets — ChEMBL curated mechanism

ADRA2A ADRA2B ADRA2C ADRB2 AGTR1 AVPR1A AVPR1B AVPR2 BDKRB2 CALCR CHRNA3 CHRNB4 ESR1 ESR2 GHSR GNRHR GSC1 HSPA8 MALT1 MC1R MC4R NOS1 NOS2 NOS3 OPRK1 OXTR RAMP1 RAMP2 RAMP3 SCN5A SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 dacA dacB dacC folP ftsI mrcA mrcB mrdA rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

	gene	UniProt	supporting neighbours	confidence
▸	DGAT1	O75907	20/20	0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL10176498	0.97	DGAT1 (0.51)	DGAT1
SCHEMBL16787542	0.90	DGAT1 (0.52)	DGAT1
SCHEMBL10177482	0.89	DGAT1 (0.48)	DGAT1
SCHEMBL9937174	0.87	DGAT1 (0.50)	DGAT1
SCHEMBL10176535	0.86	DGAT1 (0.50)	DGAT1
SCHEMBL15293798	0.86	DGAT1 (0.48)	DGAT1
SCHEMBL20428831	0.85	DGAT1 (0.48)	DGAT1
SCHEMBL10176825	0.84	DGAT1 (0.54)	DGAT1
SCHEMBL21064881	0.83	DGAT1 (0.46)	DGAT1
SCHEMBL10178159	0.83	DGAT1 (0.49)	DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-9975871-B2	Continuous arycyclic compound	MITSUBISHI TANABE PHARMA CORPORATION (JP)	2018-05-22	—	—	US	disclosed
US-20160272614-A1	CONTINUOUS ARYCYCLIC COMPOUND	MITSUBISHI TANABE PHARMA CORPORATION (JP)	2016-09-22	—	—	US	disclosed
EP-2651915-B1	CONTINUOUS ARYCYCLIC COMPOUND	MITSUBISHI TANABE PHARMA CORP (JP)	2016-05-25	—	—	EP	disclosed
US-9302996-B2	Continuous arycyclic compound	MITSUBISHI TANABE PHARMA CORPORATION (JP)	2016-04-05	—	—	US	disclosed
EP-2651915-A1	CONTINUOUS ARYCYCLIC COMPOUND	Mitsubishi Tanabe Pharma Corporation (JP)	2013-10-23	—	—	EP	disclosed
US-20130261128-A1	CONTINUOUS ARYCYCLIC COMPOUND	MITSUBISHI TANABE PHARMA CORPORATION (JP)	2013-10-03	—	—	US	disclosed
WO-2012081736-A1	CONTINUOUS ARYCYCLIC COMPOUND	MITSUBISHI TANABE PHARMA CORPORATION (JP)	2012-06-21	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130261128-A1	CONTINUOUS ARYCYCLIC COMPOUND	DGAT1, DGAT2, SOAT1	DGAT1 1/4885
US-20160272614-A1	CONTINUOUS ARYCYCLIC COMPOUND	DGAT1, DGAT2, SOAT1	DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.